Cargando…

Vitiligoid hypopigmentation associated with pembrolizumab in metastatic head and neck cancer

Cutaneous adverse events are common with the use of immunotherapy. Although only 5% of patients develop severe reactions, about half will develop mild to moderate cutaneous adverse events. Vitiligo has been seen in melanomas treated with checkpoint inhibitors (CPI). We describe the first known case...

Descripción completa

Detalles Bibliográficos
Autor principal: Bulbul, Ajaz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6440267/
https://www.ncbi.nlm.nih.gov/pubmed/30949354
http://dx.doi.org/10.1093/omcr/omz016
_version_ 1783407357402808320
author Bulbul, Ajaz
author_facet Bulbul, Ajaz
author_sort Bulbul, Ajaz
collection PubMed
description Cutaneous adverse events are common with the use of immunotherapy. Although only 5% of patients develop severe reactions, about half will develop mild to moderate cutaneous adverse events. Vitiligo has been seen in melanomas treated with checkpoint inhibitors (CPI). We describe the first known case of Vitiligoid irAE (immune-related adverse event) in a non-melanoma solid cancer treated with pembrolizumab.
format Online
Article
Text
id pubmed-6440267
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-64402672019-04-04 Vitiligoid hypopigmentation associated with pembrolizumab in metastatic head and neck cancer Bulbul, Ajaz Oxf Med Case Reports Case Report Cutaneous adverse events are common with the use of immunotherapy. Although only 5% of patients develop severe reactions, about half will develop mild to moderate cutaneous adverse events. Vitiligo has been seen in melanomas treated with checkpoint inhibitors (CPI). We describe the first known case of Vitiligoid irAE (immune-related adverse event) in a non-melanoma solid cancer treated with pembrolizumab. Oxford University Press 2019-03-29 /pmc/articles/PMC6440267/ /pubmed/30949354 http://dx.doi.org/10.1093/omcr/omz016 Text en © The Author(s) 2019. Published by Oxford University Press. http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Case Report
Bulbul, Ajaz
Vitiligoid hypopigmentation associated with pembrolizumab in metastatic head and neck cancer
title Vitiligoid hypopigmentation associated with pembrolizumab in metastatic head and neck cancer
title_full Vitiligoid hypopigmentation associated with pembrolizumab in metastatic head and neck cancer
title_fullStr Vitiligoid hypopigmentation associated with pembrolizumab in metastatic head and neck cancer
title_full_unstemmed Vitiligoid hypopigmentation associated with pembrolizumab in metastatic head and neck cancer
title_short Vitiligoid hypopigmentation associated with pembrolizumab in metastatic head and neck cancer
title_sort vitiligoid hypopigmentation associated with pembrolizumab in metastatic head and neck cancer
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6440267/
https://www.ncbi.nlm.nih.gov/pubmed/30949354
http://dx.doi.org/10.1093/omcr/omz016
work_keys_str_mv AT bulbulajaz vitiligoidhypopigmentationassociatedwithpembrolizumabinmetastaticheadandneckcancer